Vanguard Group Inc. Has $16.80 Million Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Vanguard Group Inc. lessened its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 3.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,506,287 shares of the biopharmaceutical company’s stock after selling 125,002 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Vanda Pharmaceuticals worth $16,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in VNDA. SG Americas Securities LLC boosted its position in shares of Vanda Pharmaceuticals by 26.8% during the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 5,459 shares in the last quarter. Franklin Resources Inc. lifted its stake in Vanda Pharmaceuticals by 8.8% during the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 4,449 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Vanda Pharmaceuticals during the fourth quarter valued at approximately $649,000. FMR LLC grew its stake in shares of Vanda Pharmaceuticals by 25.9% in the 3rd quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after purchasing an additional 30,802 shares during the period. Finally, Barclays PLC raised its holdings in shares of Vanda Pharmaceuticals by 128.2% in the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock worth $722,000 after buying an additional 86,677 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $4.37 on Thursday. The business has a fifty day moving average price of $4.60 and a 200 day moving average price of $4.69. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.85 and a fifty-two week high of $6.75. The stock has a market capitalization of $254.84 million, a price-to-earnings ratio of -13.66 and a beta of 0.72.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The company had revenue of $53.19 million during the quarter, compared to analyst estimates of $51.00 million. On average, equities analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

VNDA has been the topic of a number of analyst reports. StockNews.com initiated coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Tuesday, April 1st.

Insider Transactions at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was bought at an average price of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the transaction, the chief executive officer now directly owns 2,331,730 shares in the company, valued at $10,399,515.80. The trade was a 0.43 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 32,000 shares of company stock worth $151,180. Corporate insiders own 8.90% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.